Regulation of Good Clinical Practice (GCP) Enforcement in China

1. Introduction

Good Clinical Practice (GCP) is a system of ethical and scientific standards governing the design, conduct, recording, supervision, and reporting of clinical trials involving human participants. In China, GCP enforcement aims to protect the rights, safety, and welfare of trial participants while ensuring the reliability and integrity of clinical research data.

China’s GCP framework is particularly important for pharmaceutical biotechnology, innovative medicines, vaccines, medical devices, and international multicentre clinical trials. Enforcement combines regulatory inspections, institutional ethics review, sponsor accountability, investigator obligations, and administrative penalties.

The principal regulatory authority is the National Medical Products Administration (NMPA), working with provincial medical products administrations and other relevant authorities.

2. Principal Legal and Regulatory Framework

A. Drug Administration Law of the People’s Republic of China

The Drug Administration Law, revised in 2019, provides the overarching statutory framework for drug research, clinical trials, manufacturing, marketing authorisation, and post-market supervision.

Its significance for GCP enforcement includes:

Requiring clinical trials to comply with applicable legal and technical standards.

Establishing regulatory supervision of drug research and clinical trial institutions.

Enabling inspections and investigations into suspected violations.

Providing administrative liability for unlawful drug research, misleading documentation, and other violations covered by the statute.

Where trial misconduct compromises the safety of participants or the authenticity of research data, the authorities may investigate the responsible institution, sponsor, investigator, or other regulated party, depending on the violation and applicable legal provision.

B. NMPA Good Clinical Practice Regulations

China’s revised Good Clinical Practice for Drug Trials, issued jointly by the NMPA and the National Health Commission in 2020, took effect on 1 July 2020.

The rules establish requirements concerning:

Ethical protection: Participants must receive appropriate information and provide informed consent before participating, subject to applicable legal requirements.

Scientific validity: Trials must follow an approved protocol and scientifically justified methods.

Investigator responsibility: Investigators must supervise trial conduct, maintain accurate records, and report safety information as required.

Sponsor responsibility: Sponsors must ensure appropriate trial organisation, quality management, monitoring, and oversight.

Data integrity: Trial records must be accurate, complete, traceable, and verifiable.

Safety reporting: Adverse events and serious adverse events must be documented and handled according to the applicable rules.

Quality assurance: Monitoring, audits, inspections, and corrective measures must support compliance throughout the trial.

GCP is therefore not merely a set of professional recommendations. Its requirements operate within China’s binding drug regulatory framework.

C. 2026 Revised GCP

An important current-law development is that China issued a revised GCP in 2026, effective 1 September 2026, replacing the 2020 version. The revised framework incorporates principles associated with ICH E6(R3) and updates the standards governing clinical-trial quality management. Accordingly, as of October 2026, the 2026 GCP is the relevant standard for current compliance, subject to applicable transitional arrangements.

lexiscn.com

+1

D. Drug Clinical Trial Institution Supervision and Inspection Measures, 2023

The NMPA issued the Measures for the Supervision and Inspection of Drug Clinical Trial Institutions (Trial Implementation) in November 2023, effective from 1 March 2024. These measures formalise inspection procedures, regulatory coordination, assessment of institutional compliance, and the handling of inspection findings.

nmpa.gov.cn

+1

3. Institutional Mechanism for GCP Enforcement

China enforces GCP through several connected institutions.

NMPA: Establishes national drug regulatory requirements, oversees compliance, and takes or coordinates regulatory action.

Center for Food and Drug Inspection (CFDI): Conducts or supports inspections and verification of clinical-trial data.

Provincial drug regulatory authorities: Perform inspections and enforcement functions within their jurisdictions.

National Health Commission and health authorities: Exercise relevant responsibilities concerning medical institutions, healthcare professionals, and research governance.

Institutional ethics committees: Review trial protocols, informed-consent materials, risks, and participant safeguards.

Enforcement may involve routine or risk-based inspections, inspections connected with registration applications, investigations prompted by suspected misconduct, and follow-up assessments after corrective action.

4. Major GCP Compliance Obligations

A. Informed consent and ethical review

Under Articles 20 and 21 of the Drug Administration Law, drug clinical trials require ethics committee review and approval. Participants must receive truthful information about the trial’s objectives and risks and provide voluntary informed consent.

Failure to obtain valid consent can undermine the ethical legitimacy of the trial and expose responsible parties to regulatory or civil liability, depending on the facts.

B. Data integrity and documentation

Sponsors and investigators must ensure that clinical-trial records accurately reflect what occurred. Fabricated participant records, altered laboratory results, missing source documents, or inconsistent records of investigational drugs can cause data to be rejected or the trial to fail inspection.

C. Safety monitoring

Article 22 requires sponsors to respond promptly when safety problems or other risks emerge. Depending on the circumstances, this may require protocol amendments, suspension or termination of the trial, and reporting to the NMPA.

D. Sponsor and contract research organisation accountability

Delegating trial activities to a contract research organisation (CRO) does not make compliance irrelevant to the sponsor. Investigators, CRO personnel, and sponsors may face different consequences according to their actual conduct, responsibilities, and the applicable legal provisions.

5. Enforcement and Legal Consequences

Regulatory responses depend on the nature and seriousness of the violation. They may include:

Orders to correct deficiencies.

Reinspection and enhanced supervision.

Rejection or withdrawal of clinical-trial registration applications.

Suspension or termination of trials where legally justified.

Administrative penalties under the Drug Administration Law and related rules.

Criminal prosecution where fraudulent documentation or other conduct satisfies the elements of a criminal offence.

Civil liability where a participant suffers legally compensable harm.

Article 126 of the Drug Administration Law is specifically relevant to certain failures by drug clinical-trial institutions to comply with GCP and other prescribed requirements. Article 125 addresses unauthorised clinical trials, while Article 127 covers specified other violations, including failures concerning safety-related action and reporting. The precise provision depends on the conduct established.

National Medical Products Administration

+1

6. Important Case Laws and Enforcement Precedents

Published Chinese judicial decisions specifically interpreting GCP provisions are less readily identifiable than administrative enforcement materials. The following authorities are therefore particularly relevant, although the first is a binding judicial interpretation rather than an individual court judgment.

Case 1: Supreme People’s Court and Supreme People’s Procuratorate Judicial Interpretation (2017)

Subject: Fabrication of drug and medical-device registration data.

The Supreme People’s Court and Supreme People’s Procuratorate issued the Interpretation on Several Issues Concerning the Application of Law in Criminal Cases Involving Fabrication of Drug and Medical Device Registration Application Materials, effective 1 September 2017.

The interpretation clarifies that personnel of clinical-trial institutions and CROs who intentionally provide false clinical-trial reports may commit the offence of providing false certification documents under Article 229 of China’s Criminal Law.

Serious circumstances expressly addressed include fabricating participant information or trial data, destroying original records, concealing serious adverse events, and intentionally using false investigational drugs.

Legal significance: The interpretation establishes that GCP-related misconduct can extend beyond administrative non-compliance into criminal liability. It also addresses liability for persons who direct or knowingly participate in the fabrication of registration materials.

spp.gov.cn

+1

Case 2: NMPA Clinical-Trial Data Verification Initiative (2015–2017)

Subject: Regulatory verification of clinical-trial data supporting drug registration.

China’s drug regulator conducted extensive on-site verification of clinical-trial data submitted with new drug applications. A subsequent research analysis reported that, among 313 applications inspected between July 2015 and June 2017, 38 were suspected of data fabrication.

The initiative involved examination of source records, trial procedures, participant information, and the reliability of submitted data.

Legal significance: This enforcement precedent demonstrates that regulators may scrutinise the underlying evidence rather than merely accept a sponsor’s submitted report. It illustrates the importance of traceability, original documentation, and consistency between source data and registration submissions. The figures indicate suspected fabrication, not necessarily final findings of criminal guilt in every case.

Wiley Online Library

+1

Case 3: NMPA Announcement on Clinical-Trial Data Verification (15 October 2019)

Subject: Self-examination and verification of registration applications.

The NMPA announced verification of seven drug registration applications and stated that applicants, responsible personnel, clinical-trial managers, and CRO personnel found involved in data fraud during on-site verification would face serious legal consequences.

The announcement also provided an opportunity for applicants to withdraw applications voluntarily after discovering data inauthenticity through self-examination, subject to the announced conditions.

Legal significance: This regulatory precedent highlights the importance of proactive compliance, internal audits, and prompt identification of data-integrity problems. It also demonstrates that responsibility may extend across the sponsor, research institution, and CRO.

National Medical Products Administration

+1

7. Critical Assessment

China’s GCP enforcement framework combines ethical review, institutional inspections, data verification, administrative sanctions, and criminal prosecution. Its effectiveness depends on whether institutions maintain reliable original records, report safety issues promptly, and ensure genuine oversight of delegated research activities.

The 2026 revision strengthens the importance of applying the current GCP standard to trial quality management. Institutions should therefore review their standard operating procedures, training programmes, sponsor–CRO agreements, documentation systems, and inspection-readiness arrangements against the revised requirements.

A further distinction is essential: an inspection deficiency is not automatically proof of fraud, and an administrative enforcement action is not necessarily a judicial precedent. Legal conclusions must be based on the established facts and the particular statutory provisions involved.

8. Conclusion

GCP enforcement in China is a legally significant component of pharmaceutical regulation. The Drug Administration Law establishes the statutory foundation, the NMPA and related authorities supervise compliance, and the judicial interpretation on registration-data fabrication provides a route to criminal accountability in serious cases.

The central principle is that clinical-trial data must be scientifically reliable, ethically obtained, and capable of independent verification. Failure to meet these standards can jeopardise a drug’s registration, expose institutions and individuals to administrative sanctions, and, where the legal elements are satisfied, result in criminal prosecution.